PepGen (PEPG) Share-based Compensation (2021 - 2026)
PepGen (PEPG) posted Share-based Compensation of $2.9 million for Q1 2026, up 17.15% sequentially from $2.4 million in Q4 2025, and down 16.81% YoY from $3.4 million in Q1 2025.
PepGen (PEPG) Share-based Compensation (2021 - 2026) Analysis & Trends
PepGen has reported Share-based Compensation for 6 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Share-based Compensation fell 16.81% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (down 13.73% YoY) and the FY2025 annual result came in at $15.8 million, down 46.8% from the prior year.
- Share-based Compensation improved to $2.9 million in Q1 2026 per PEPG's latest filing, from $2.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $25.6 million in Q2 2025 and troughed at $815000.0 in Q1 2022.
- A 5-year average of $4.8 million and a median of $2.4 million in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 3359.64% in 2022, then plunged 91.7% in 2023.
- Over 5 years, Share-based Compensation stood at $23.1 million in 2022, then slumped by 91.7% to $1.9 million in 2023, then soared by 74.14% to $3.3 million in 2024, then fell by 27.19% to $2.4 million in 2025, then rose by 17.15% to $2.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.9 million, $2.4 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | PepGen | 207.09 Mn | 207.09 Mn | - | 20.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.40 Mn |
| Jun 30, 2026 | 20.40 Mn |
| Mar 31, 2026 | 2.86 Mn |
| Mar 31, 2026 | 2.86 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Dec 31, 2025 | 2.44 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 25.60 Mn |
| Jun 30, 2025 | 25.60 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.02 Mn |